Xvivo is scheduled to release the results for the quarter ended March 31, 2019, on Wednesday, April 24, 2019, before the stock market opens. Following the release, the company will host a telephone conference at 2:00 p.m. We expect to see continued strong growth of sales related to warm perfusion. Further, focus will be on updates on the status of the upcoming trials with HS1/Heartadex as well as PrimECC.